Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19763814 | 0.92 | RET (1.00) | RET | |
| SCHEMBL22369952 | 0.90 | RET (0.86) | RET | |
| SCHEMBL19763843 | 0.90 | RET (1.00) | RET | |
| SCHEMBL19763880 | 0.90 | RET (1.00) | RET | |
| SCHEMBL19763830 | 0.90 | RET (1.00) | RET | |
| SCHEMBL19763852 | 0.89 | RET (1.00) | RET | |
| SCHEMBL19763851 | 0.89 | RET (1.00) | RET | |
| SCHEMBL19763853 | 0.87 | RET (1.00) | RET | |
| SCHEMBL22369968 | 0.87 | RET (0.90) | RET | |
| SCHEMBL29588894 | 0.86 | RET (0.87) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108697714-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2022-04-26 | — | — | CN | claimed |
| CN-108697714-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11008324-B2 | — | — | 2021-05-18 | — | — | US | disclosed |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-20200270253-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20190330214-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-31 | — | — | US | disclosed |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330214-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | RET 1/4885 |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | RET 1/4885 |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | RET 1/4885 |
| US-11008324-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885 |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | RET 1/4885 |
| US-20200270253-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.